Targeting of the BRAF gene in papillary thyroid carcinoma (Review)

Oncology Reports

Volumn 22, Issue 4, 2009, Pages 671-681

  Li, Yaqiong ^a,c   Nakamura, Misa ^b   Kakudo, Kennichi ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^b OSAKA KAWASAKI REHABILITATION UNIVERSITY   (Japan)

^c SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

BRAFV600E mutation; Histological variants; Papillary carcinoma; Prognosis; Signaling pathway; Target therapy; Thyroid

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 5 (4 BROMO 2 CHLOROANILINO) 4 FLUORO 1 METHYL 1H BENZIMIDAZOLE 6 CARBOHYDROXAMIC ACID 2 HYDROXYETHYL ESTER; ANTINEOPLASTIC AGENT; B RAF KINASE; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; CERAMIDE; IODINE 131; MITOGEN ACTIVATED PROTEIN KINASE; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; NEUROTROPHIC RECEPTOR TYROSINE KINASE TYPE 1; PLX 4032; PLX 4720; PROTEIN KINASE INHIBITOR; RAF PROTEIN; RAS PROTEIN; ROTTERLIN; SMALL INTERFERING RNA; SORAFENIB; UNCLASSIFIED DRUG;

ALLELE; APOPTOSIS; CANCER DIAGNOSIS; CANCER INHIBITION; CANCER MORTALITY; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG POTENCY; DRUG POTENTIATION; EXPRESSION VECTOR; GENE MUTATION; GENE REARRANGEMENT; GENE TARGETING; GENETIC ASSOCIATION; GENETIC VARIABILITY; HISTOPATHOLOGY; HUMAN; IC 50; MONOTHERAPY; MORBIDITY; PAPILLARY THYROID CARCINOMA; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RELIABILITY; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVIEW; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; THYROID CARCINOMA; THYROIDECTOMY;

ADENOCARCINOMA, PAPILLARY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; THYROID NEOPLASMS;

EID: 70350364867     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000487     Document Type: Review

References (104)

1. Davies L and Welch HG: Increasing incidence of thyroid cancer in the United States, 1973-2002 JAMA 295: 2164-2167, 2006.
2. Leenhardt L, Grosclaude P and Cherie-Challine L: Increased incidence of thyroid carcinoma in france: a true epidemic or thyroid nodule management effects? Report from the French Thyroid Cancer Committee. Thyroid 14: 1056-1060, 2004.
3. DeLellis RA, Lloyd RV, Heitz PU and Eng C (eds): World Health Organization Classification of Tumours, Pathology and Genetics of Tumours of Endocrine Organs. IARCPress, Lyon, 2004.
4. Hundahl SA, Cady B, Cunningham MP, Mazzaferri E, McKee RF, Rosai J, Shah JP, Fremgen AM, Stewart AK and Holzer S: Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the united states during 1996. U.S. and German Thyroid Cancer Study Group. An American College of Surgeons Commission on Cancer Patient Care Evaluation study. Cancer 89: 202-217, 2000.
5. Kakudo K, Bai Y, Katayama S, Hirokawa M, Ito Y, Miyauchi A and Kuma K: Classification of follicular cell tumors of the thyroid gland: analysis involving Japanese patients from one institute. Pathol Int 59: 359-367, 2009.
6. Hundahl SA, Fleming ID, Fremgen AM and Menck HR: A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer 83: 2638-2648, 1998.
7. Santoro M, Melillo RM, Carlomagno F, Fusco A and Vecchio G: Molecular mechanisms of RET activation in human cancer. Ann NY Acad Sci 963: 116-121, 2002.
8. Greco A, Pierotti MA, Bongarzone I, Pagliardini S, Lanzi C and Della Porta G: TRK-T1 is a novel oncogene formed by the fusion of TPR and TRK genes in human papillary thyroid carcinomas. Oncogene 7: 237-242, 1992.
9. Esapa CT, Johnson SJ, Kendall-Taylor P, Lennard TW and Harris PE: Prevalence of Ras mutations in thyroid neoplasia. Clin Endocrinol (Oxf) 50: 529-535, 1999.
10. Cohen Y, Xing M, Mambo E, Guo Z, Wu G, Trink B, Beller U, Westra WH, Ladenson PW and Sidransky D: BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 95: 625-627, 2003.
11. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE and Fagin JA: High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 63: 1454-1457, 2003.
12. Riesco-Eizaguirre G and Santisteban P: New insights in thyroid follicular cell biology and its impact in thyroid cancer therapy. Endocr Relat Cancer 14: 957-977, 2007.
13. Xing M: BRAF mutation in thyroid cancer. Endocr Relat Cancer 12: 245-262, 2005.
14. Miller CJ, Cheung M, Sharma A, Clarke L, Helm K, Mauger D and Robertson GP: Method of mutation analysis may contribute to discrepancies in reports of (V599E)BRAF mutation frequencies in melanocytic neoplasms. J Invest Dermatol 123: 990-992, 2004.
15. Hay R, MacRae E, Barber D, Khalil M and Demetrick DJ: BRAF mutations in melanocytic lesions and papillary thyroid carcinoma samples identified using melting curve analysis of polymerase chain reaction products. Arch Pathol Lab Med 131: 1361-1367, 2007.
16. Rowe LR, Bentz BG and Bentz JS: Detection of BRAF V600E activating mutation in papillary thyroid carcinoma using PCR with allele-specific fluorescent probe melting curve analysis. J Clin Pathol 60: 1211-1215, 2007.
17. Benlloch S, Paya A, Alenda C, Bessa X, Andreu M, Jover R, Castells A, Llor X, Aranda FI and Massuti B: Detection of BRAF V600E mutation in colorectal cancer: comparison of automatic sequencing and real-time chemistry methodology. J Mol Diagn 8: 540-543, 2006.
18. Hayashida N, Namba H, Kumagai A, Hayashi T, Ohtsuru A, Ito M, Saenko VA, Maeda S, Kanematsu T and Yamashita S: A rapid and simple detection method for the BRAF(T1796A) mutation in fine-needle aspirated thyroid carcinoma cells. Thyroid 14: 910-915, 2004.
19. Xing M, Tufano RP, Tufaro AP, Basaria S, Ewertz M, Rosenbaum E, Byrne PJ, Wang J, Sidransky D and Ladenson PW: Detection of BRAF mutation on fine needle aspiration biopsy specimens: a new diagnostic tool for papillary thyroid cancer. J Clin Endocrinol Metab 89: 2867-2872, 2004.
20. Sapio MR, Posca D, Troncone G, Pettinato G, Palombini L, Rossi G, Fenzi G and Vitale M: Detection of BRAF mutation in thyroid papillary carcinomas by mutant allele-specific PCR amplification (MASA). Eur J Endocrinol 154: 341-348, 2006.
21. Saldanha G, Purnell D, Fletcher A, Potter L, Gillies A and Pringle JH: High BRAF mutation frequency does not characterize all melanocytic tumor types. Int J Cancer 111: 705-710, 2004.
22. Xing M: BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases and clinical implications. Endocr Rev 28: 742-762, 2007.
23. Ito Y, Yoshida H, Maruo R, Morita S, Takano T, Hirokawa M, Yabuta T, Fukushima M, Inoue H, Tomoda C, Kihara M, Uruno T, Higashiyama T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F and Miyauchi A: BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients. Endocr J 56: 89-97, 2009.
24. Kim TY, Kim WB, Song JY, Rhee YS, Gong G, Cho YM, Kim SY, Kim SC, Hong SJ and Shong YK: The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma. Clin Endocrinol (Oxf) 63: 588-593, 2005.
25. Zuo H, Nakamura Y, Yasuoka H, Zhang P, Nakamura M, Mori I, Miyauchi A and Kakudo K: Lack of association between BRAF V600E mutation and mitogen-activated protein kinase activation in papillary thyroid carcinoma. Pathol Int 57: 12-20, 2007.
26. Frattini M, Ferrario C, Bressan P, Balestra D, De Cecco L, Mondellini P, Bongarzone I, Collini P, Gariboldi M, Pilotti S, Pierotti MA and Greco A: Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. Oncogene 23: 7436-7440, 2004.
27. Soares P, Trovisco V, Rocha AS, Lima J, Castro P, Preto A, Maximo V, Botelho T, Seruca R and Sobrinho-Simoes M: BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene 22: 4578-4580, 2003.
28. De Groot JW, Links TP, Plukker JT, Lips CJ and Hofstra RM: RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors. Endocr Rev 27: 535-560, 2006.
29. Santoro M, Melillo RM and Fusco A: RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture. Eur J Endocrinol 155: 645-653, 2006.
30. Nikiforov YE: Thyroid carcinoma: molecular pathways and therapeutic targets. Mod Pathol 21 (Suppl. 2): S37-S43, 2008.
31. Tuveson DA, Weber BL and Herlyn M: BRAF as a potential therapeutic target in melanoma and other malignancies. Cancer Cell 4: 95-98, 2003.
32. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR and Futreal PA: Mutations of the BRAF gene in human cancer. Nature 417: 949-954, 2002.
33. Ciampi R, Knauf JA, Kerler R, Gandhi M, Zhu Z, Nikiforova MN, Rabes HM, Fagin JA and Nikiforov YE: Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. J Clin Invest 115: 94-101, 2005.
34. Trovisco V, Vieira de Castro I, Soares P, Maximo V, Silva P, Magalhaes J, Abrosimov A, Guiu XM and Sobrinho-Simoes M: BRAF mutations are associated with some histological types of papillary thyroid carcinoma. J Pathol 202: 247-251, 2004.
35. Moretti S, Macchiarulo A, De Falco V, Avenia N, Barbi F, Carta C, Cavaliere A, Melillo RM, Passeri L, Santeusanio F, Tartaglia M, Santoro M and Puxeddu E: Biochemical and molecular characterization of the novel BRAF(V599Ins) mutation detected in a classic papillary thyroid carcinoma. Oncogene 25: 4235-4240, 2006.
36. Oler G, Ebina KN, Michaluart P Jr, Kimura ET and Cerutti J: Investigation of BRAF mutation in a series of papillary thyroid carcinoma and matched-lymph node metastasis reveals a new mutation in metastasis. Clin Endocrinol (Oxf) 62: 509-511, 2005.
37. Hou P, Liu D and Xing M: Functional characterization of the T1799-1801del and A1799-1816ins BRAF mutations in papillary thyroid cancer. Cell Cycle 6: 377-379, 2007.
38. De Falco V, Giannini R, Tamburrino A, Ugolini C, Lupi C, Puxeddu E, Santoro M and Basolo F: Functional characterization of the novel T599I-VKSRdel BRAF mutation in a follicular variant papillary thyroid carcinoma. J Clin Endocrinol Metab 93: 4398-4402, 2008.
39. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, Jones CM, Marshall CJ, Springer CJ, Barford D and Marais R: Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116: 855-867, 2004.
40. Sala E, Mologni L, Truffa S, Gaetano C, Bollag GE and Gambacorti-Passerini C: BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells. Mol Cancer Res 6: 751-759, 2008.
41. Ciampi R and Nikiforov YE: RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis. Endocrinology 148: 936-941, 2007.
42. Wang X, Wang Q, Hu W and Evers BM: Regulation of phorbol ester-mediated TRAF1 induction in human colon cancer cells through a PKC/RAF/ERK/ NF-kappaB-dependent pathway. Oncogene 23: 1885-1895, 2004.
43. Knauf JA, Ma X, Smith EP, Zhang L, Mitsutake N, Liao XH, Refetoff S, Nikiforov YE and Fagin JA: Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res 65: 4238-4245, 2005.
44. Espinosa AV, Porchia L and Ringel MD: Targeting BRAF in thyroid cancer. Br J Cancer 96: 16-20, 2007.
45. Adeniran AJ, Zhu Z, Gandhi M, Steward DL, Fidler JP, Giordano TJ, Biddinger PW and Nikiforov YE: Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol 30: 216-222, 2006.
46. Apel RL, Asa SL and LiVolsi VA: Papillary Hurthle cell carcinoma with lymphocytic stroma. 'Warthin-like tumor' of the thyroid. Am J Surg Pathol 19: 810-814, 1995.
47. Fink A, Tomlinson G, Freeman JL, Rosen IB and Asa SL: Occult micropapillary carcinoma associated with benign follicular thyroid disease and unrelated thyroid neoplasms. Mod Pathol 9: 816-820, 1996.
48. Harach HR, Franssila KO and Wasenius VM: Occult papillary carcinoma of the thyroid. A 'normal' finding in Finland. A systematic autopsy study. Cancer 56: 531-538, 1985.
49. Yamamoto Y, Maeda T, Izumi K and Otsuka H: Occult papillary carcinoma of the thyroid. A study of 408 autopsy cases. Cancer 65: 1173-1179, 1990.
50. Sugg SL, Ezzat S, Rosen IB, Freeman JL and Asa SL: Distinct multiple RET/ PTC gene rearrangements in multifocal papillary thyroid neoplasia. J Clin Endocrinol Metab 83: 4116-4122, 1998.
51. Tallini G, Santoro M, Helie M, Carlomagno F, Salvatore G, Chiappetta G, Carcangiu ML and Fusco A: RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes. Clin Cancer Res 4: 287-294, 1998.
52. Soares P, Fonseca E, Wynford-Thomas D and Sobrinho-Simoes M: Sporadic ret-rearranged papillary carcinoma of the thyroid: a subset of slow growing, less aggressive thyroid neoplasms? J Pathol 185: 71-78, 1998.
53. Nikiforov YE, Rowland JM, Bove KE, Monforte-Munoz H and Fagin JA: Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Res 57: 1690-1694, 1997.
54. Thomas GA, Bunnell H, Cook HA, Williams ED, Nerovnya A, Cherstvoy ED, Tronko ND, Bogdanova TI, Chiappetta G, Viglietto G, Pentimalli F, Salvatore G, Fusco A, Santoro M and Vecchio G: High prevalence of RET/ PTC rearrangements in Ukrainian and Belarussian post-Chernobyl thyroid papillary carcinomas: a strong correlation between RET/PTC3 and the solid-follicular variant. J Clin Endocrinol Metab 84: 4232-4238, 1999.
55. Rabes HM, Demidchik EP, Sidorow JD, Lengfelder E, Beimfohr C, Hoelzel D and Klugbauer S: Pattern of radiation-induced RET and NTRK1 rearrangements in 191 post-Chernobyl papillary thyroid carcinomas: biological, phenotypic, and clinical implications. Clin Cancer Res 6: 1093-1103, 2000.
56. Lee JH, Lee ES, Kim YS, Won NH and Chae YS: BRAF mutation and AKAP9 expression in sporadic papillary thyroid carcinomas. Pathology 38: 201-204, 2006.
57. - targeting to the membrane. Endocr Relat Cancer 13: 257-269, 2006.
58. Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, Zhu Z, Giannini R, Salvatore G, Fusco A, Santoro M, Fagin JA and Nikiforov YE: BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 88: 5399-5404, 2003.
59. Namba H, Nakashima M, Hayashi T, Hayashida N, Maeda S, Rogounovitch TI, Ohtsuru A, Saenko VA, Kanematsu T and Yamashita S: Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab 88: 4393-4397, 2003.
60. Trovisco V, Soares P, Preto A, De Castro IV, Lima J, Castro P, Maximo V, Botelho T, Moreira S, Meireles AM, Magalhaes J, Abrosimov A, Cameselle-Teijeiro J and Sobrinho-Simoes M: Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients' age but not with tumour aggressiveness. Virchows Arch 446: 589-595, 2005.
61. Lee X, Gao M, Ji Y, Yu Y, Feng Y, Li Y, Zhang Y, Cheng W and Zhao W: Analysis of differential BRAF(V600E) mutational status in high aggressive papillary thyroid microcarcinoma. Ann Surg Oncol 16: 240-245, 2009.
62. Sheu SY, Schwertheim S, Worm K, Grabellus F and Schmid KW: Diffuse sclerosing variant of papillary thyroid carcinoma: lack of BRAF mutation but occurrence of RET/PTC rearrangements. Mod Pathol 20: 779-787, 2007.
63. Lee JH, Lee ES and Kim YS: Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis. Cancer 110: 38-46, 2007.
64. Lam AK and Lo CY: Diffuse sclerosing variant of papillary carcinoma of the thyroid: a 35-year comparative study at a single institution. Ann Surg Oncol 13: 176-181, 2006.
65. Thompson LD, Wieneke JA and Heffess CS: Diffuse sclerosing variant of papillary thyroid carcinoma: a clinicopathologic and immunophenotypic analysis of 22 cases. Endocr Pathol 16: 331-348, 2005.
66. Salvatore G, Giannini R, Faviana P, Caleo A, Migliaccio I, Fagin JA, Nikiforov YE, Troncone G, Palombini L, Basolo F and Santoro M: Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma. J Clin Endocrinol Metab 89: 5175-5180, 2004.
67. Bai Y, Kakudo K, Li Y, Liu Z, Ozaki T, Ito Y, Kihara M and Miyauchi A: Subclassification of non-solid-type papillary thyroid carcinoma identification of high-risk group in common type. Cancer Sci 99: 1908-1915, 2008.
68. Xu X, Quiros RM, Gattuso P, Ain KB and Prinz RA: High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res 63: 4561-4567, 2003.
69. Durante C, Puxeddu E, Ferretti E, Morisi R, Moretti S, Bruno R, Barbi F, Avenia N, Scipioni A, Verrienti A, Tosi E, Cavaliere A, Gulino A, Filetti S and Russo D: BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J Clin Endocrinol Metab 92: 2840-2843, 2007.
70. Fugazzola L, Mannavola D, Cirello V, Vannucchi G, Muzza M, Vicentini L and Beck-Peccoz P: BRAF mutations in an Italian cohort of thyroid cancers. Clin Endocrinol (Oxf) 61: 239-243, 2004.
71. Fugazzola L, Puxeddu E, Avenia N, Romei C, Cirello V, Cavaliere A, Faviana P, Mannavola D, Moretti S, Rossi S, Sculli M, Bottici V, Beck-Peccoz P, Pacini F, Pinchera A, Santeusanio F and Elisei R: Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. Endocr Relat Cancer 13: 455-464, 2006.
72. Jo YS, Li S, Song JH, Kwon KH, Lee JC, Rha SY, Lee HJ, Sul JY, Kweon GR, Ro HK, Kim JM and Shong M: Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer. J Clin Endocrinol Metab 91: 3667-3670, 2006.
73. Kebebew E, Weng J, Bauer J, Ranvier G, Clark OH, Duh QY, Shibru D, Bastian B and Griffin A: The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg 246: 466-471, 2007.
74. Kim KH, Kang DW, Kim SH, Seong IO and Kang DY: Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population. Yonsei Med J 45: 818-821, 2004.
75. Kim TY, Kim WB, Rhee YS, Song JY, Kim JM, Gong G, Lee S, Kim SY, Kim SC, Hong SJ and Shong YK: The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma. Clin Endocrinol (Oxf) 65: 364-368, 2006.
76. Liu RT, Chen YJ, Chou FF, Li CL, Wu WL, Tsai PC, Huang CC and Cheng JT: No correlation between BRAFV600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan. Clin Endocrinol (Oxf) 63: 461-466, 2005.
77. Lupi C, Giannini R, Ugolini C, Proietti A, Berti P, Minuto M, Materazzi G, Elisei R, Santoro M, Miccoli P and Basolo F: Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. J Clin Endocrinol Metab 92: 4085-4090, 2007.
78. Park SY, Park YJ, Lee YJ, Lee HS, Choi SH, Choe G, Jang HC, Park SH, Park do J and Cho BY: Analysis of differential BRAF(V600E) mutational status in multifocal papillary thyroid carcinoma: evidence of independent clonal origin in distinct tumor foci. Cancer 107: 1831-1838, 2006.
79. Rodolico V, Cabibi D, Pizzolanti G, Richiusa P, Gebbia N, Martorana A, Russo A, Amato MC, Galluzzo A and Giordano C: BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyroid ≤1 cm and their paired lymph node metastases. Cancer 110: 1218-1226, 2007.
80. Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ, Carson KA, Vasko V, Larin A, Tallini G, Tolaney S, Holt EH, Hui P, Umbricht CB, Basaria S, Ewertz M, Tufaro AP, Califano JA, Ringel MD, Zeiger MA, Sidransky D and Ladenson PW: BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 90: 6373-6379, 2005.
81. Elisei R, Ugolini C, Viola D, Lupi C, Biagini A, Giannini R, Romei C, Miccoli P, Pinchera A and Basolo F: BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin Endocrinol Metab 93: 3943-3949, 2008.
82. Puxeddu E, Durante C, Avenia N, Filetti S and Russo D: Clinical implications of BRAF mutation in thyroid carcinoma. Trends Endocrinol Metab 19: 138-145, 2008.
83. Kim SK, Kim DL, Han HS, Kim WS, Kim SJ, Moon WJ, Oh SY and Hwang TS: Pyrosequencing analysis for detection of a BRAFV600E mutation in an FNAB specimen of thyroid nodules. Diagn Mol Pathol 17: 118-125, 2008.
84. Matsukuma S, Yoshihara M, Kasai F, Kato A, Yoshida A, Akaike M, Kobayashi O, Nakayama H, Sakuma Y, Yoshida T, Kameda Y, Tsuchiya E and Miyagi Y: Rapid and simple detection of hot spot point mutations of epidermal growth factor receptor, BRAF, and NRAS in cancers using the loop-hybrid mobility shift assay. J Mol Diagn 8: 504-512, 2006.
85. Chung KW, Yang SK, Lee GK, Kim EY, Kwon S, Lee SH, Park do J, Lee HS, Cho BY, Lee ES and Kim SW: Detection of BRAFV600E mutation on fine needle aspiration specimens of thyroid nodule refines cyto-pathology diagnosis, especially in BRAF600E mutation-prevalent area. Clin Endocrinol (Oxf) 65: 660-666, 2006.
86. Liao KT, Cheng JT, Li CL, Liu RT and Huang HJ: Ultrasensitive detection of mutated papillary thyroid carcinoma DNA using square wave stripping voltammetry method and amplified gold nanoparticle biomarkers. Biosens Bioelectron 15: 1899-1904, 2009.
87. Chiloeches A and Marais R: Is BRAF the Achilles' Heel of thyroid cancer? Clin Cancer Res 12: 1661-1664, 2006.
88. Samaan NA, Schultz PN, Hickey RC, Goepfert H, Haynie TP, Johnston DA and Ordonez NG: The results of various modalities of treatment of well differentiated thyroid carcinomas: a retrospective review of 1599 patients. J Clin Endocrinol Metab 75: 714-720, 1992.
89. Liu D, Liu Z, Jiang D, Dackiw AP and Xing M: Inhibitory effects of the mitogen-activated protein kinase kinase inhibitor CI-1040 on the proliferation and tumor growth of thyroid cancer cells with BRAF or RAS mutations. J Clin Endocrinol Metab 92: 4686-4695, 2007.
90. Salvatore G, De Falco V, Salerno P, Nappi TC, Pepe S, Troncone G, Carlomagno F, Melillo RM, Wilhelm SM and Santoro M: BRAF is a therapeutic target in aggressive thyroid carcinoma. Clin Cancer Res 12: 1623-1629, 2006.
91. Liu D, Liu Z, Condouris S and Xing M: BRAF V600E maintains proliferation, transformation and tumorigenicity of BRAF-mutant papillary thyroid cancer cells. J Clin Endocrinol Metab 92: 2264-2271, 2007.
92. Liu D, Hu S, Hou P, Jiang D, Condouris S and Xing M: Suppression of BRAF/ MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant. Clin Cancer Res 13: 1341-1349, 2007.
93. Pushparaj PN, Aarthi JJ, Manikandan J and Kumar SD: siRNA, miRNA, and shRNA: in vivo applications. J Dent Res 87: 992-1003, 2008.
94. Ouyang B, Knauf JA, Smith EP, Zhang L, Ramsey T, Yusuff N, Batt D and Fagin JA: Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo. Clin Cancer Res 12: 1785-1793, 2006.
95. Tsai J, Lee JT, Wang W, Zhang J, Cho H, Mamo S, Bremer R, Gillette S, Kong J, Haass NK, Sproesser K, Li L, Smalley KS, Fong D, Zhu YL, Marimuthu A, Nguyen H, Lam B, Liu J, Cheung I, Rice J, Suzuki Y, Luu C, Settachatgul C, Shellooe R, Cantwell J, Kim SH, Schlessinger J, Zhang KY, West BL, Powell B, Habets G, Zhang C, Ibrahim PN, Hirth P, Artis DR, Herlyn M and Bollag G: Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci USA 105: 3041-3046, 2008.
96. Kane RC, Farrell AT, Saber H, Tang S, Williams G, Jee JM, Liang C, Booth B, Chidambaram N, Morse D, Sridhara R, Garvey P, Justice R and Pazdur R: Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res 12: 7271-7278, 2006.
97. Eisen T, Ahmad T, Flaherty KT, Gore M, Kaye S, Marais R, Gibbens I, Hackett S, James M, Schuchter LM, Nathanson KL, Xia C, Simantov R, Schwartz B, Poulin-Costello M, O'Dwyer PJ and Ratain MJ: Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer 95: 581-586, 2006.
98. Madhunapantula SV and Robertson GP: Is B-Raf a good therapeutic target for melanoma and other malignancies? Cancer Res 68: 5-8, 2008.
99. Jane EP, Premkumar DR and Pollack IF: Coadministration of sorafenib with rottlerin potently inhibits cell proliferation and migration in human malignant glioma cells. J Pharmacol Exp Ther 319: 1070-1080, 2006.
100. Sharma A, Trivedi NR, Zimmerman MA, Tuveson DA, Smith CD and Robertson GP: Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res 65: 2412-2421, 2005.
101. Ball DW, Jin N, Rosen DM, Dackiw A, Sidransky D, Xing M and Nelkin BD: Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244. J Clin Endocrinol Metab 92: 4712-4718, 2007.
102. Garnett MJ and Marais R: Guilty as charged: B-RAF is a human oncogene. Cancer Cell 6: 313-319, 2004.
103. Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A, Ye Q, Lobo JM, She Y, Osman I, Golub TR, Sebolt-Leopold J, Sellers WR and Rosen N: BRAF mutation predicts sensitivity to MEK inhibition. Nature 439: 358-362, 2006.
104. Leboeuf R, Baumgartner JE, Benezra M, Malaguarnera R, Solit D, Pratilas CA, Rosen N, Knauf JA and Fagin JA: BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines. J Clin Endocrinol Metab 93: 2194-2201, 2008.